NEJM Editorial Demands For More Data In Trial Registry Draw Industry Flak
Executive Summary
Pfizer and other drug makers are rebuffing criticism from the New England Journal of Medicine that they failed to participate fully in HHS' ongoing initiative to spur registration of clinical trials